Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Most clinical trials of non‐small‐cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kano, Hirohisa, Ichihara, Eiki, Harada, Daijiro, Inoue, Koji, Kayatani, Hiroe, Hosokawa, Shinobu, Kishino, Daizo, Watanabe, Kazuhiko, Ochi, Nobuaki, Oda, Naohiro, Hara, Naofumi, Ninomiya, Kiichiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540975/
https://www.ncbi.nlm.nih.gov/pubmed/32726470
http://dx.doi.org/10.1111/cas.14590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540975/
https://www.ncbi.nlm.nih.gov/pubmed/32726470
http://dx.doi.org/10.1111/cas.14590

Ejemplares similares